מחיר חזוי לרווח: Aethlon (AEMD)

Aethlon Medical (AEMD) relies on external financing, as its primary developments are undergoing clinical validation without a stable cash flow. Aethlon Medical creates defensive solutions in collaboration with state defense orders and specialized centers. The developer of Hemopurifier is patenting methods for blood purification from exosomes in oncology. The company's forward P/E ratio reflects market expectations, with the current value equal to 0.00.

The forward P/E reflects market expectations by comparing the current share price with projected future net income to assess the premium paid for future earnings. For Aethlon Medical (AEMD), which is burning capital on clinical trials without generating sales, the company's expected P/E level demonstrates the highly speculative nature of the assets in the complete absence of operating cash flow.